Physician profile
David E Winner
NPI 1285627125
$6,841.33
in general payments reported to CMS, 2019-2025
51 companies · $1,416 in 2025
The $1,416 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $493 · 2021: $884 · 2022: $1,063 · 2023: $1,265 · 2024: $1,193 · 2025: $1,416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,873.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $996.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $733.88 | 2019-2025 | |
| Abbvie INC. | $697.47 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $502.57 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Lilly USA, LLC | $467.13 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $436.31 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $393.81 | 2019-2025 | Prolia, Evenity, Otezla |
| Glaxosmithkline, LLC. | $261.09 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $188.68 | 2023-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $181.23 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $166.40 | 2019-2023 | |
| Biohaven Pharmaceuticals, INC. | $141.72 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $121.18 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $116.42 | 2024-2025 | Auvelity |
| Sanofi-Aventis U.S. LLC | $111.95 | 2019-2021 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Winner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.